Key Points
- ICON director Ciaran Murray sold 10,000 shares for about $2.0 million at an average price of $200.18, reducing his direct holdings by 58.82% to 7,000 shares. He had also sold 3,452 shares earlier in November.
- ICON’s latest quarterly results modestly beat estimates: earnings were $2.66 per share versus $2.62 expected, and revenue was $2.02 billion versus $2.01 billion expected. Revenue was down 0.9% year over year.
- Analysts’ average rating is Moderate Buy, with an average price target of $213.76; the article reports a mix of one Strong Buy, nine Buy, nine Hold, and one Sell rating.
Icon Plc (NASDAQ:ICLR - Get Free Report) Director Ciaran Murray sold 10,000 shares of the business's stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $200.18, for a total value of $2,001,800.00. Following the sale, the director directly owned 7,000 shares of the company's stock, valued at approximately $1,401,260. This trade represents a 58.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Ciaran Murray also recently made the following trade(s):
- On Monday, November 2nd, Ciaran Murray sold 3,452 shares of Icon stock. The stock was sold at an average price of $205.66, for a total value of $709,938.32.
Icon Stock Performance
Icon stock opened at $191.40 on Tuesday. The stock's 50-day moving average is $179.55 and its 200-day moving average is $147.45. The company has a market cap of $14.66 billion, a price-to-earnings ratio of 32.94, a price-to-earnings-growth ratio of 11.11 and a beta of 1.19. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.32 and a quick ratio of 1.32. Icon Plc has a 12 month low of $66.57 and a 12 month high of $219.04.
Icon (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.62 by $0.04. Icon had a return on equity of 7.73% and a net margin of 5.45%. The business had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same period in the previous year, the company posted $3.31 EPS. The company's revenue was down .9% compared to the same quarter last year. Equities analysts anticipate that Icon Plc will post 9.71 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on the stock. Truist Financial raised their price target on shares of Icon from $209.00 to $268.00 and gave the company a "buy" rating in a report on Thursday, October 29th. Deutsche Bank reiterated a "buy" rating and set a $250.00 price objective on shares of Icon in a research note on Thursday, October 29th. Bank of America raised shares of Icon from an "underperform" rating to a "neutral" rating and set a $185.00 price objective for the company in a research report on Friday, October 9th. Weiss Ratings raised shares of Icon from a "sell (d)" rating to a "sell (d+)" rating in a research report on Wednesday, October 28th. Finally, Zacks Research raised shares of Icon from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $213.76.
Get Our Latest Research Report on ICLR
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of ICLR. Pathstone Holdings LLC grew its stake in shares of Icon by 15.5% in the third quarter. Pathstone Holdings LLC now owns 29,193 shares of the medical research company's stock valued at $4,962,000 after buying an additional 3,927 shares in the last quarter. First Trust Advisors LP raised its holdings in shares of Icon by 330.5% during the 3rd quarter. First Trust Advisors LP now owns 8,654 shares of the medical research company's stock valued at $1,471,000 after buying an additional 6,644 shares during the period. Heartland Advisors Inc. raised its holdings in shares of Icon by 17.7% during the 3rd quarter. Heartland Advisors Inc. now owns 53,974 shares of the medical research company's stock valued at $9,175,000 after buying an additional 8,131 shares during the period. Stephens Investment Management Group LLC raised its holdings in shares of Icon by 7.1% during the 3rd quarter. Stephens Investment Management Group LLC now owns 771,246 shares of the medical research company's stock valued at $131,104,000 after buying an additional 50,985 shares during the period. Finally, Muhlenkamp & Co. Inc. lifted its position in Icon by 1.1% during the 3rd quarter. Muhlenkamp & Co. Inc. now owns 67,038 shares of the medical research company's stock worth $11,396,000 after acquiring an additional 701 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company's stock.
Icon Company Profile
(
Get Free Report)
ICON plc is a global contract research organization (CRO) that provides outsourced development services to pharmaceutical, biotechnology, medical device and government organizations. Its work supports the development of medicines and other healthcare products from early research through clinical trials and regulatory submission. The company's services include clinical trial design and management, data management and biostatistics, regulatory support, laboratory services, medical imaging and patient recruitment.
Read More

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].